What are the best treatments for Graft Versus Host Disease?

TL;DR: The primary treatment for Graft Versus Host Disease (GVHD) is systemic immunosuppression, typically starting with high-dose corticosteroids to control immune system activity. Because Graft Versus Host Disease manifests differently in every patient, treatment is highly personalized and often involves a multidisciplinary team to manage symptoms and prevent long-term complications.

What are the first-line treatments for Graft Versus Host Disease?

The standard of care for both acute and chronic Graft Versus Host Disease begins with corticosteroids, such as prednisone or methylprednisolone (Solu-Medrol). These medications work by broadly suppressing the immune response. If patients do not respond sufficiently to steroids, clinicians may introduce secondary therapies, including calcineurin inhibitors like tacrolimus (Prograf) or cyclosporine (Neoral), to further stabilize the immune system.

What are the common pharmacological and non-pharmacological therapies?

Beyond systemic steroids, management of Graft Versus Host Disease often requires specialized interventions based on the affected organs:

• Extracorporeal Photopheresis (ECP): An immunomodulatory procedure where white blood cells are treated outside the body with light-activated drugs.


• Topical therapies: Steroid creams, tacrolimus ointments, or eye drops (such as autologous serum tears) for skin and ocular involvement.


• Physical and Occupational Therapy: Essential for patients experiencing joint contractures or muscle weakness caused by sclerodermatous Graft Versus Host Disease.


• Targeted Agents: Ruxolitinib (Jakafi) is an FDA-approved treatment for steroid-refractory acute and chronic Graft Versus Host Disease.

Which specialists should be on the care team?

Because Graft Versus Host Disease is a systemic condition, a multidisciplinary approach is vital. Your care team should ideally include a hematologist-oncologist specializing in bone marrow transplantation, along with dermatologists, ophthalmologists, gastroenterologists, and physical therapists. At DiseaseMaps.org, 50 members have shared their experiences with Graft Versus Host Disease, highlighting the importance of coordinated care across these specialties.

What does the future of treatment look like?

Research into Graft Versus Host Disease is rapidly evolving. Current clinical trials are investigating novel pathways, including mesenchymal stromal cell therapy and newer selective kinase inhibitors, aiming to modulate the immune system more precisely while reducing side effects. Treatment effectiveness varies significantly based on the severity of the disease and the specific organs involved, necessitating frequent monitoring by your transplant team.

Next steps

• Consult your transplant physician to discuss if your current response to Graft Versus Host Disease warrants a trial of secondary agents.


• Join the DiseaseMaps.org community to connect with other patients managing Graft Versus Host Disease.


• Review active clinical trials for Graft Versus Host Disease on ClinicalTrials.gov to see if you are eligible for emerging therapies.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; please consult your healthcare team for personalized treatment decisions.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Graft-versus-host disease


• National Marrow Donor Program (Be The Match): Understanding GVHD


• Orphanet: Graft versus host disease


• Blood & Marrow Transplant Clinical Trials Network (BMT CTN)